Isofol And 4D - A Sorry Tale Of Two Battered Biotechs
Under The Shadow Of Liquidation
The fear of going out of business before getting a drug submitted to regulators is one that a couple of European biotechs have had to face up to this week.
You may also be interested in...
The Belgian drugmaker’s faith in the psoriasis drug is looking to be well placed and with other indications coming aboard, sales forecasts of around €5bn-6bn for the pipeline-in-a-product seem very achievable.
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.